InSpire MD to Announce Six-Month Results From The MGuard™ Embolic Protection Stent (EPS) MASTER Trial at EuroPCR
5/17/2013 6:57:34 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ –
InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a robust schedule of educational events and data presentations at EuroPCR, culminating in the first presentation of 6-month results from the MASTER (MGuardfor Acute STElevation Reperfusion) trial of the Company’s MGuard™ Embolic Protection Stent (EPS).
Help employers find you! Check out all the jobs and post your resume.
comments powered by